{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR242/037/SRR24299137/SRR24299137.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR242/038/SRR24299138/SRR24299138.fastq.gz"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["IZBI"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA961679"],"scientific_name":["Mus musculus"],"tag":["xref:PubMed:37236597"],"long_description":["Skin-injury and several diseases elicit fibrosis and induce hair follicle (HF)-growth arrest and loss. Resulting alopecia and disfiguration represent a severe burden for patients both physically and psychologically. Reduction of pro-fibrotic factors such as DPP4 might be a strategy to tackle this issue. We demonstrate DPP4-overrepresentation in settings with HF-growth arrest (telogen), HF-loss and non-regenerative wound areas in mice skin and human scalp. Topical DPP4-inhibition (DPP4i) with FDA/EMA-approved Sitagliptin (Sit) on preclinical models of murine HF-activation/regeneration results in accelerated anagen-progress, while treatment of wounds with Sit results in reduced expression of fibrosis markers, increased induction of anagen around wounds, and HF-regeneration in the wound center. These effects are associated with higher expression of Wnt-target Lef1, known to be required for HF-anagen (HF-activation)/regeneration. Sit-treatment decreases pro-fibrotic signaling in the skin, induce a differentiation trajectory of HF-cells, and activate Wnt-targets related to HF-activation/growth but not those supporting fibrosis. Taken together, our study demonstrates a role for DPP4 in HF biology and shows how DPP4i, currently used as oral medication to treat diabetes, could be repurposed into a topical treatment agent to potentially reverse HF-loss in alopecia and after injury. Overall design: Intradermal injection of Sitagliptin or PBS (conrol), 48 h after processing of the skin for scRNAseq"],"repository":["ENA"],"description_synonyms":["Regenerations, THAM, folliculus pili, Follicles, PP4 19C, ADCP2, DPPIV, DmelCG32505, DmPpp4-19C, CG18339, CG32505, PPX, Dpp-4, Cd26, Hair, Endogenous Regeneration, Follicle, PP4C, PP1, CG1596, Regeneration, PPP4c, Endogenous., PP4, pp4, PpX, CD26, TP103, activation, Hair Follicles, dPP4, ADABP, CG1459"],"name_synonyms":["Regenerations, THAM, folliculus pili, Follicles, PP4 19C, ADCP2, DPPIV, DmelCG32505, DmPpp4-19C, CG18339, CG32505, PPX, Dpp-4, Cd26, Hair, Endogenous Regeneration, Follicle, PP4C, PP1, CG1596, Regeneration, PPP4c, Endogenous., PP4, pp4, PpX, CD26, TP103, activation, Hair Follicles, dPP4, ADABP, CG1459"],"additional_accession":[]},"is_claimable":false,"name":"Repurposing DPP4-Inhibition to Improve Hair Follicle Activation and Regeneration","description":"Repurposing DPP4-Inhibition to Improve Hair Follicle Activation and Regeneration","dates":{"last_updated":"2025-09-24","first_public":"2023-05-05"},"accession":"PRJNA961679","cross_references":{"GEO":["GSE230514"],"taxon":["10090"],"PubMed":["37236597"]}}